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1. Introduction
Electrocardiographic  changes  were  mentioned  in  several  noncardiac  diseases,  due  to
multiple mechanisms: changes of the position of the heart, autonomic imbalance, hormo‐
nal  abnormalities,  interposition  of  fluid  or  tissue  between  the  heart  and the  electrodes,
increased blood pressure, cardiomyopathy of systemic diseases, electrolyte imbalances, or
due to therapy [1, 2].
A  prolonged  ECG  QT  interval  and  an  increased  QT  dispersion  (QTd,  the  difference  be‐
tween the longest  and shortest  QT interval  duration in  all  12  standard ECG leads),  are
markers of ventricular arrythmia risk. Sudden cardiac death, a major public health problem,
is caused, mainly, by ventricular fibrillation [3].
Besides a prolonged QT interval, longer than 450 ms in male and 460 ms in female [4], late
ventricular  potentials  (LVPs),  which  are  low  amplitude  and  high  frequency  waveforms,
appearing in the terminal part of the QRS complex, and are markers of an electrophysiolog‐
ical  substrate  for  reentry  ventricular  arrythmias  in  a  diseased  myocardium,  were  also
detected in several extracardiac diseases using signal averaged ECG [5].
Standard 12-lead ECG provides a bedside snapshot of the electrial activity of the heart, but
Holter electrocardiogarphy enables detection of episodes of arrhythmia and evaluate therapeu‐
tic interventions [6].
2. Objective
The aim of the present chapter was to provide a concise overview of available data regarding
epidemiology  and  pathophysiology  of  ventricular  arrhythmias  in  several  noncardiac
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diseases, to mention the main methods used to assess arrhythmia risk, as well as to elucidate
their  relation  to  long-term  outcome.  Dyslipidemia,  obesity,  diabetes  mellitus,  liver,
hematologic, neurologic and psychiatric disorders, are discussed.
3. Dyslipidaemia and ventricular arrhythmia risk
Elevated LDL cholesterol was associated with all manifestations of coronary artery disease
including sudden cardiac death [7]. Hypercholesterolemia is not only atherogenic, but is also
associated  with  autonomic  imbalance,  alteration  of  the  contractile  properties  of  the
myocardium, increased oxidative stress and ventricular electrophysiological remodeling [8,
9]. Myocardial electrical remodeling due to hypercholesterolemia caused prolonged action
potential  durations,  longer  QTc (heart  rate  corrected QT interval  durations),  conduction
slowing and increased repolarization dispersion [9, 10].
Several  clinical  and  autopsy  studies  demonstrated  an  association  between  elevated
cholesterol levels and sudden cardiac death [11, 12].  Gualdiero et al.  reported a positive
correlation  between  cholesterol  level,  QT dispersion  and premature  ventricular  contrac‐
tions in patients with isolated hypercholesterolemia, and normalization of serum cholester‐
ol  and QT dispersion and improvement of  ventricular  ectopic  activity,  with simvastatin
[13]. Szabo et al. found significant correlations of QT interval duration and QT dispersion
with total and LDL cholesterol, triglycerides and apoplipoprotein B, respectively, in patients
with type IIb hyperlipoproteinemia, without myocardial ischemia, suggesting a direct effect of
hyperlipidemia on ventricular repolarization [14]. LDL increases the cholesterol to phospho‐
lipid ratio in the cell membrane, enhancing membrane rigidity and impairing functionali‐
ty of the ion channels and ventricular repolarization [14, 15]. Ventricular repolarization is
reflected by the QT interval on the ECG, which is regulated mainly by potassium chan‐
nels.  On  the  other  hand,  type  II  hyperlipoproteinemia  is  characterized  by  accelerated
atherosclerosis, related to small dense LDL synthesis.
It  was  also  hypothesized  that  hypercholesterolemia  causes  repolarization  abnormalities,
probably, by beta or IK channel phosphorylation mediated mechanisms [9]. Hypercholester‐
olemia  causes  also  endothelial  dysfunction,  with  impaired  microvascular  vasodilatation,
facilitating vasoconstriction, and electrical heterogeneity and extrasystolic activity [13]. The
increase in the QT interval duration in cholesterol fed rabbits was lesser if L-Arginine was
supplemented,  suggesting  a  beneficial  role  of  L-Arginine  (a  nitric  acid  precusror)  in
hypercholesterolemia  induced  repolarization  characteristics  [9].  L-Arginine  increases
endogenous nitric oxide, which may activate ATP dependent K channels, shortening the
action potential [9].
Late ventricular potentials  were detected in patients with high and moderately elevated
serum cholesterol [5, 16].
Cardiac Arrhythmias - Mechanisms, Pathophysiology, and Treatment90
Statins  have  antiarrhythmic  properties,  exhibiting  a  protective  effect  against  the  occur‐
rence of ventricular arrhythmias and atrial fibrillation, in addition to their lipid-lowering
and anti-atherogenic  effects  [5,  12,  13,  17,  18].  The main mechanisms explaining,  proba‐
bly,  the  antiarrhythmic  properties  of  statins  are  as  follows:  prevention  of  ischemia-in‐
duced electrophysiological effects that predispose to ventricular arrhythmias and ischemia-
induced oxidative  stress,  decrease in  ischemia-induced myocyte  hypertrophy,  reverse  of
neural  remodeling  induced  by  hypercholesterolemia,  increase  of  heart  rate  variability,
decrease of QT interval duration and variability, reversion of electrophysiological remodel‐
ing  induced  by  hypercholesterolemia,  increase  in  parasympathetic  tone,  changes  in
transmembrane  ion  channel  properties,  decrease  of  the  incidence  of  late  ventricular
potentials [10, 12].
4. Ventricular arrhythmias in obesity and eating disorders
Morbid obesity  was associated with high rates of sudden cardiac death [19, 20]. Lalani et
al. reported a high prevalence of abnormal signal averaged ECGs in obese without known
cardiovascular  disease  [20].  An  increased  QT  dispersion  was  found  in  obese  women,
associated with left ventricular hypertrophy [21] and prolonged QT intervals were measured
in obese patients [22-24]. Several mechanisms explain the high sudden cardiac death risk
in obese,  including: parasympathetic withdrawal,  conduction abnormalities,  cardiomyop‐
athy of obesity with cardiomegaly and myocyte hypertrohy, lipotoxicity of the myocardi‐
um induced by free fatty acids, released from hypertrophied adipocytes in obese persons
with myocardial steatosis, structural heterogeneity due to fatty infiltration of the heart, focal
myocardial  disarray,  fibrosis and mononuclear cell  infiltration [5,  19,  20,  25,  26].  Prema‐
ture ventricular contractions (PVCs) are very prevalent in obese [27] and sudden cardiac
death risk is increased in obese compared to normal weighted survivors of a myocardial
infarction [28].
Weight loss causes a shortening of the QT interval, correlated with diastolic blood pressure
decrease, and changes in time and frequency domain parameters of heart rate variability,
with  recovery  of  the  physiological  autonomic  control  (increase  in  parasympathetic  and
reduction in sympathetic indices [29].
QT prolongation, signal averaged ECG abnormalities and late ventricular potentials were
reported  in  eating  disorders,  including  both  anorexia  and  bulimia  nervosa  [30].  Bulimia
nervosa, an eating disorder characterized by binge eating and purging, was associated with
QT interval  prolongation,  related to  electrolyte  imbalances,  especially  hypokalemia  [31].
Anorexia  nervosa  carries  the  highest  mortality  of  any  psychiatric  disorder,  very  often
attributable  to  sudden  cardiac  death.  Delayed  cardiac  repolarization  and  QT  prolonga‐
tion, not correlated with disease severity, were reported [32]. Any patient with an eating
disorder should undergo standard 12-lead ECG.
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Disease Mechanisms Methods andarrhythmia
Obesity
parasympathetic withdrawal, conduction abnormalities,
cardiomyopathy of obesity, lipotoxicity of the
myocardium induced by free fatty acids, structural
heterogeneity due to fatty infiltration of the heart, focal











Bulimia nervosa electrolyte imbalances (hypokalemia) QT, LVPs
Diabetes mellitus
autonomic imbalance, oxidative stress, increased cytosolic






cirrhotic cardiomyopathy, cardiac ion channel




cardiac autonomic imbalance, neural interventions,
norepinephrine, calcium influx, myocytolysis,
hypokalemia, concomitant myocardial ischemia and heart




VT, R/T, VF, Vf
Holter monitoring
Intracranial hemorrhage intraventricular blood, hydrocephalus QTcPVCs, TdP




autonomic disturbance (intrinsic or iatrogenic),
cardiovascular comorbidities, electrolyte imbalances,
degeneration of cardioselective neurons
QT
Epilepsy
sympathovagal imbalance, impaired cardiac
repolarization, dysfunction of cortical networks, ictal
hypoxemia and hypercapnia, stress hormones,







left ventricular hypertrophy, sympathetic nervous system
activation, oxidative stress, chronic inflammation,




Table 1. Mechanisms of ventricular arrhythmias and methods used to assess sudden cardiac risk in some extracardiac
diseases
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5. Glucose metabolism disorders and ventricular arrhythmia risk
Several studies associate diabetes mellitus and hyperglycemia with sudden cardiac death,
related to QT interval prolongation, appearance of late ventricular potentials, impaired
depolarization and repolarization, enhanced sympathetic activity, oxidative stress, increased
cytosolic calcium content, defective phosphoinositide 3-kinase signaling with increased
persistent sodium current, premature and accelerated atherosclerosis, transient hypoglycemic
episodes due to drug therapy, duration of diabetes, and renal failure, as target-organ damage,
causing electrolyte imbalances [5, 33-36]. QT interval prolongation and increase of QT
dispersion are predictive for sudden cardiac death in patients with type 1 and 2 diabetes
mellitus [37]. QT interval duration was independently associated with glycated hemoglobin in
patients with type 1 diabetes mellitus [38], and hyperinsulinemia and insulinresistance can
contribute to QTc prolongation [39]. Li et al found a high prevalence of prolonged QTc
intervals, and low height, high waist circumference, increased diastolic blood pressure levels,
high postprandial glucose levels, high fasting insulin and presence of microalbuminuria, as
risk factors for QTc prolongation among Chinese patients with type 2 diabetes mellitus [40].
Stress hyperglycemia on admission was found to be a predictor of mortality and arrhythmias in
patients with acute myocardial infarction and could be used in the stratification of risk in these
patients [5, 41, 42]. An independent association between hyperglycemia and prolonged QTc
and increased QT dispersion was found in healthy, nondiabetic subjects [39].
Severe hypoglycemia is also associated with ventricular repolarization abnormalities, prolon‐
gation of the QT interval, and ventricular arrhythmias [35]. QTc interval prolongation was
observed during the episodes of sever hypoglycemia compared to the recovered stage, in
patients with type 2 diabetes mellitus, associated with increase in serum catecholamines,
altered neural regulation and hypokalemia [43, 44]. The likelihood of ventricular arrhythmias
is increased, particularly when hypoglycemia occurs in a patient with autonomic neuropathy
[35]. Sudden nocturnal death in young people with type 1 diabetes could be due to cardiac
arrhythmias induced by hypoglycemia [45]. Hypokalemia, caused by hyperinsulinemia and
intracellular shift of potassium, could explain the altered cardiac repolarization during the
episodes of hypoglycemia [43].
6. Liver diseases and ventricular arrhythmia risk
Several cardiac problems have been reported in patienst with liver cirrhosis, including chro‐
notrope incompetence, cardiomyopathy and prolonged QT intervals, proportional to the
Child-Pugh class [46]. A prolonged QT interval represents the most common electrocardio‐
graphic (ECG) finding in patients with liver cirrhosis and is the electrophysiological hallmark
of “cirrhotic cardiomyopathy” [47, 48, 49 ]. Cirrhotic cardiomyopathy can appear in all forms
of cirrhosis and includes systolic and diastolic dysfunction and electrophysiological abnor‐
malities, in the absence of any known cardiac disease [48]. Cardiac ion channels remodeling
has been noticed in patients with liver cirrhosis, with impaired K and Ca channels, due to
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endotoxins and increased biliary acids, which alter beta-adrenoreceptor, G protein and ionic
channels in patients with cholestasis [46].
QT prolongation in liver pathology was first described in alcoholic liver diseases [50]. Alcohol
effects on life-threatening arrhythmias correlate directly with the amount and duration of
alcohol intake; even small quantities are significant in susceptible individuals [35]. Further
studies reported prolonged QT intervals in patients with primary biliary cirrhosis and other
chronic non-alcoholic liver diseases, related to the severity of the autonomic neuropathy, and
could detect patients with increased cardiovascular risk [51]. QT interval prolongation was
related to the pathophysiology of cirrhosis itself and not to a specific cause of cirrhosis [52].
Prolonged QTc intervals were related to the presence of portal hypertension, including mild
portal hypertension, and liver dysfunction [53]. Genovesi et al. reported significant correla‐
tions between QTc and each of the following: plasma calcium level, portal hypertension, and
the hepatic venous pressure gradient [47]. Liver disease severity, alcoholic etiology, and serum
uric acid were associated with prolonged QT interval in patients with liver cirrhosis, according
to another study [48]. Liver transplantation may revert cardiac dysfunction [54] and prolonged
QTc returns to normal values, in most of the patients, after liver transplantation, suggesting
that liver disease may not be the only factor in the pathogenesis of prolonged QTc [52, 55].
Acute gastrointestinal bleeding was found to further prolong QTc in patients with liver
cirrhosis, and QTc prolongation predicted bleeding induced mortality [56].
Concluding, the mechanisms by which liver cirrhosis affects ventricular repolarization are as
follows: electrolyte imbalances, impaired autonomic function, subclinical cardiomyopathy,
reduced β-adrenoreceptor function, postreceptor pathway defects, altered physical properties
of myocyte plasma membrane, elevated levels of cardiotoxins, ion channel remodeling,
portosystemic shunting and systemic circulatory disturbances [46-48, 53, 54, 57].
The clinical significance of QT prolongation in liver cirrhosis is unclear, considering that
sudden cardiac death and torsades de pointes are rare [58].
QTc interval was also measured in patients with chronic hepatitis C, showing non-significant
increases six months after starting combination therapy with pegylated interferon and
ribavirin, in order to achieve sustained virological response [59].
7. Cerebrogenic arrhythmias and ventricular arrhythmia risk in neurologic
diseases
Cardiac diseases are a well-known stroke risk factors and complicate stroke outcome [60].
Cardiac arrhythmias and electrocardiographic abnormalities are frequently observed after
acute cerebrovascular events, even in the absence of structural heart disease [61]. With
improved survival after major cardiovascular events and aging of the population, stroke
followed by myocardial infarction and arrhythmias will be an increasing clinical entity in the
coming decades [60]. The neurologic event is the main cause of death only in the first week
after stroke [62]. After the first year, cardiovascular diseases are the main cause of death in
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stroke patients [63]. Atrial fibrillation, the most common arrhythmia in clinical practice, is a
major risk factor for embolic stroke [60, 64]. Stroke and subarachnoid hemorrhage cause other
cerebrogenic ECG findings as well, prolong the QT interval, increase QT dispersion and
ventricular arrhythmia risk, mainly due to an autonomic nervous system dysregulation [1, 61,
65, 66 ]. Large, inverted T waves following a prolonged QTc interval, common after subar‐
achnoid hemorrhage, are often termed as “cerebral” or “neurogenic” [67]. Brady- and tachyar‐
rhythmia, including polymorphic ventricular tachycardia (PVT), have been also described in
the setting of neurologic injury [68]. The greatest risk of arrhythmias is, probably, within the
first 24 h after stroke, with a marked decline in time [69]. Activation of both sympathetic and
parasympathetic systems has cumulative effect in the development of arrhythmias and
myocardial damage after cerebral incidents, and the damage of the hypothalamic, insular, and
brainstem region is crucial for the genesis of cardiac arrhythmias, due to neural connections
with other cortical sites and the autonomic nervous system [61]. Sander et al, found increased
norepinephrine levels in patients with insular infarction, significantly related to adverse
outcome and QTc [70]. The sympathetic system has a major role in the pathogenesis of
hypokalemia and may indirectly result in QTc prolongation after subarachnoid hemorrhage
[61]. Probably constant catecholamine stimulation of beta-adrenoreceptors linked to mem‐
brane Na+/K+-ATPases causes a potassium influx, resulting in hypokalemia, and thus precip‐
itating ventricular arrhythmias [62]. Both reduced heart-rate variability (HRV) and impaired
baroreceptor reflex sensitivity (BRS) suggest impaired physiological central and cardiac
autonomic reflex function [62]. Ventricular arrhythmogenesis following stroke, related to the
cardiac autonomic imbalance is explained by two hypotheses [62]. The first involves damage
to central nervous structures controlling the autonomic nervous system, resulting in sympa‐
thetic amplification or parasympathetic inhibition, with subsequent ECG changes, without
permanent myocardium damage, and the second hypothesis proposes an augmented sympa‐
thetic discharge, resulting in increased secretion of catecholamine, causing myocytolysis [62].
The insula plays an important role in autonomic nervous function imbalance after stroke [62,
71]. Involvement of the right insula decreases basal sympathetic tone and may result in
parasympathetic hyperactivity, and left insular lesions decrease parasympathetic activity and
augment cardiac sympathetic tone [71]. Sympathetic hyperactivity prolongs repolarization
duration and increases arrhythmogenesis [62].
A concomitant myocardial ischemia or necrosis, elevated blood pressure and heart failure
may  be  also  considered  [1].  Autopsy  of  stroke  patients,  who  developed  repolarization
abnormalities, revealed no obvious coronary artery atherosclerosis in most of them, and the
only findings were petechial subendocardial hemorrhages and focal myofibrillar degenera‐
tion, reproducible with intravenous administration of catecholamines or electrical stimula‐
tion of  the vagus nerve in laboratory animals  [61].  Sudden calcium influx,  mediated by
catecholamines, impairs myocardial relaxation, leads to myocytolysis, myofibrillar degener‐
ation, coronary vasoconstriction, myocardial ischemia and ECG changes, and is proarrhyth‐
mic [61, 62]. Elevated serum uric acid, direct neural interventions, inflammation, reactive
oxygen species, electrolyte imbalances, the structural and electrophysiological changes of a
senescent heart and comorbities can increase sudden cardiac death risk in stroke [61, 66].
Stroke survivors with a prolonged QT in V6,  were identified to have an increased sud‐
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den cardiac death risk [72]. Prolonged QT intervals were associated with decreased survival
rates and worse neurological outcomes at hospital discharge [73]. The prevalence of cardiac
arrhythmias  after  acute  stroke  may  reach  28%,  higher  after  subarachnoid  hemorrhage
(37.5%) and in right sided lesions [61]. The most prevalent ECG findings were, besides atrial
fibrillation,  sinus  tachycardia,  atrio-ventricular  block,  repolarization  changes,  premature
ventricular contractions, R on T phenomenon (R/T), non-sustained, sustained and polymor‐
phic  ventricular  tachycardia  (VT),  ventricular  fibrillation  (VF)  and  flutter  (Vf)  [61,  62].
Independent risk factors for the development of ventricular arrhythmias in patients with
aneurysmal subarachnoid hemorrhage were prolonged QTc and decreased heart rate, and
therapy with angiotensin converting enzyme inhibitors and angiotensin receptor blockers
was protective [74]. Literature data are insufficient to support the hypothesis that subarach‐
noid  hemorrhage  and  stroke  cause  ventricular  arrhythmias,  considering  that  in  most
patients  additional  QT  prolonging  causes  were  mentioned,  including  hypokalemia,
hypomagnesaemia,  and congenital  long QT syndrome,  and patients  with  stroke usually
have risk factors for coronary artery disease, such as hypertension, diabetes mellitus, and
smoking, or advanced age, or left ventricular hypertrophy [61, 62, 75]. Several studies did
not control pre-existing arrhythmias, were of short duration and did not explore the long-
term consequences of ventricular arrhythmogenesis [62].  Another important limitation of
most  of  the  studies  is  the  use  of  single  surface  ECG,  because  it  may  underestimate
arrhythmia incidence in the acute phase of a stroke [62]. Holter monitoring revealed a higher
incidence of ventricular arrhythmias after transient ischemic attacks, cerebral infarction and
intracerebral hemorrhage compared to patients who were not continuously monitored (56%
vs. 8%) [76].
It is also possible that in some cases, prolonged QTc actually existed before the development
of stroke and it could be used as a predictor of future stroke in the general population [75]. The
association of QTc with cardiovascular risk factors does not fully explain the prognostic
significance of QTc as a stroke predictor, but it is possible, that prolonged QTc interval is a
marker of silent undetected atherosclerotic vascular disease [75]. QTc was previously associ‐
ated with markers of subclinical atherosclerosis, including carotid intima media thickness,
arterial stiffness and endothelial dysfunction [77-80]. Probably, QTc prolongation may be a
surrogate indicator of subclinical atherosclerosis and subsequently can be predictive of future
atherosclerotic vascular events such as stroke, but it is not clear if it represents a marker, a
limited adaptive or pathological process [75].
The ECG abnormalities observed in intracranial hemorrhage may also influence clinical outcome.
QTc prolongation correlated with insular cortex involvement, presence of intraventricular
blood, and hydrocephalus on admission CT scans in patients with intracranial hemorrhage
[81]. A case of a 58-year-old woman, with several episodes of self-terminating torsade de
pointes (TdP) following nonspecific ST-T changes, and prolonged QT after brainstem hemor‐
rhage, has been reported in the literature [82]. Maramattom et al. found premature ventricular
contractions and QTc prolongation at 24 hours from admission, not related with the location,
volume and side of the hemorrhage, nor with the presence of hydrocephalus, extraparenchy‐
mal extension or troponin T elevation [83].
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It is uncertain whether ECG abnormalities are caused by the cerebrovascular event itself,
considering that in the majority of studies patients' previous ECG data were unavailable [61].
Current management after stroke focuses mostly on the neurological function [62]. The QT
interval and electrolyte levels should be monitored, and QT prolonging drugs should be
avoided in patients with acute cerebrovascular events, especially for female patients with
insular cortex lesions [61]. Multiple studies recommend continuous ECG monitoring, however,
others believe that only severely QTc interval prolongation predicts cardiac complications [62].
Follow up studies with large sample sizes, considering previous arrhythmias and coronary
heart disease, are needed, to establish the incidence of ventricular arrhythmias after stroke,
and clear guidelines for clinicians approaching stroke patients with increased ventricular
arrhythmia risk [62].
Goldberger et al. reported an unusual case of idiopathic acute encephalopathy, with persistent
fever, refractory seizure, marked ventricular repolarization with bursts of torsade de pointes,
diffuse ST elevations and Brugada-like pattern, treated with propofol [68].
Two mechanisms connecting cardiomyopathies and neurological diseases have been descri‐
bed: cardiomyopathies may either secondarily cause neurological disease or may represent
the cardiac manifestation of a neurological disease, especially neuromuscular disorders [2].
Sudden cardiac death and ventricular arrhythmias occur mainly in neurological diseases
causing hypertrophic cardiomyopathy (in adolescents and young adults), or dilated cardio‐
myopathy (among which syncope is a common clinical manifestation), or arrhythmogenic
right ventricular dysplasia [2]. Takotsubo cardiomyopathy ("the broken heart" syndrome) was
reported after stroke, subarachnoid bleeding, spontaneous intracerebral bleeding, spinal injury
and head trauma, and the patients are prone to arrhythmias, heart failure or thrombus formation
within the left ventricle during the acute phase [2]. Inherited neuromuscular disorders may
predispose to premature ventricular contractions, monomorphic and polymorphic ventricular
tachycardia and sudden cardiac death, due to degenerative changes in the myocardium [35].
Electrical abnormalities, including QTc and JTc dispersion (the difference between the longest
and shortest JT interval duration), may be the earliest manifestation of cardiomyopathy in
patients with Emery-Dreifuss muscular dystrophy, a hereditary muscle disorder characterized
by slowly progressive muscle wasting and weakness, with humero-peroneal distribution [84].
QTc and JTc dispersions (QTcd, JTcd) reflect ventricular repolarization heterogeneities, due to
diffuse fibrosis and fatty acid infiltration in Emery-Dreifuss muscular dystrophy, and if
elevated, increase the risk of development of malignant ventricular arrhythmias via early
afterdepolarization and reentry (polymorphic ventricular tachyarrhythmia), facilitated by
intramural functional conduction blocks [84]. The mechanisms underlying sudden cardiac
death in myotonic dystrophy type 1 are: bradyarrhythmias due to cardiac conduction abnormal‐
ities, and the increased values of the QT variability index, demonstrating an important heart
involvement, extended beyond the conduction system [85]. Duchenne muscular dystrophy,
related to a mutation in the dystrophin gene, the most common neuromuscular disease, causes
progressive proximal muscle weakness of the legs and pelvis and a loss of muscle mass. It
affects also the heart (myocyte degeneration, fibrosis and fatty infiltration), impairing ventric‐
ular repolarization, causing autonomic dysfunction, QTc prolongation and increase of QT
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dispersion, as an independent risk factor for ventricular arrhythmias of Lown grade III or
higher [86-88]. Late ventricular potentials were reported in patients with Duchenne muscular
dystrophy (31%), indicating the presence of a substrate for reentry ventricular arrhythmias,
associated with local myocardial fibrosis, and identifying patients at high risk for sudden
cardiac death [89]. Cardiac involvement was also mentioned in other dystrophinopathies, due
to the replacement of myocardium by connective tissue or fat, but it remains subclinical in
Duchenne and Becker muscular dystrophy [86]. Patients with primary and secondary neuro‐
muscular disorders need to be obligatorily screened for cardiac disease and ventricular
arrhythmia risk, as soon as the neurological diagnosis is established, and cardiac investigations
should be regularly repeated, especially in the case of severe cardiac involvement [2]. Once
cardiac involvement occurs, the clinician should consider invasive electrophysiological studies
and ICD implantation [35].
In Parkinson’s disease factors affecting cardiac conduction may include intrinsic or iatrogenic
autonomic disturbances, cardiovascular comorbidities (cardiac ischemia, ventricular hyper‐
trophy), and electrolyte imbalances due to diuretics [90]. The most common prescribed drugs
with QT prolonging effect were: Dromperidone, with antiemetic effect and also used to treat
symptomatic postural hypotension, Citalopram, an antidepressant, and some antimicrobial
agents (macrolides, azoles and fluoroquinolones) in a study conducted by Malek et al. [90].
Combining such drugs with some antipsychotics, tricyclic antidepressants, antihistamines and
anti-retrovirals has additive influence on QT interval prolongation [90]. Large epidemiological
studies emphasized the difficulties in detecting transient drug-induced ventricular arrhythmia
in outpatient clinics, due to too few events, despite frequent syncope [91]. Oka et al considered
that QTc intervals are closely related to autonomic nervous system dysfunction in patients
with Parkinson’s disease, related to the progression of the disease [92, 93]. Deguchi et al. found
prolonged QTc intervals in patients with Parkinson’s disease, reflecting the degeneration of
cardioselective sympathetic and parasympathetic neurons [94]. Artifacts related to muscle
tremor may affect ECGs in patients with Parkinson’s disease, but methods were found to
reduce noise and variance of QTc [95]. Drugs known to prolong the QT interval are often
prescribed in patients with Parkinson’s disease, and therapy should consider additional risk
factors, especially comorbidities, autonomic dysfunction and degeneration of cardioselective
neurons [90, 94].
Sudden unexpected death in epilepsy is probably caused by periictal cardiorespiratory
alterations, such as central apnea, bradyarrhythmia, and neurogenic pulmonary edema, and
ventricular arrhythmias [96, 97]. Sudden cardiac death in patients with seizure disorders is
facilitated by associated cardiovascular diseases, pathologic cardiac repolarization, sympa‐
thovagal imbalance and therapy used to treat the disease [35, 96, 97]. A pathologic cardiac
repolarization has been described in epileptic patients, with prolonged intercritical and
periictal QT intervals, increased QT dispersion and shortened QTc after generalized tonic-
clonic seizures, but fatal seizure-related ventricular arrhythmias are very rare [96]. On the other
hand, no LVPs and significant standard ECG abnormalities were recorded in patients with
newly diagnosed epilepsy, without clinical evidence of heart disease, three to nine months
after therapy start, demonstrating lack of antiepileptic drugs induced electrocardiographic
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abnormalities [98]. Rejdak et al. reported abnormal SAECGs and late ventricular potentials in
epilepsy patients, associated with disease duration, higher monthly seizure frequency,
refractory epilepsy and tendency for higher number of generalized tonic-clonic seizures,
polytherapy [99]. Data about intercritical QT intervals in epileptic patients are contradictory;
it was found within normal limits, shorter or longer, and antiepileptic drugs and the ketogenic
diet are potential confounders [96]. Transient dysfunction of cortical networks, as interictal
epileptiform electroencephalographic discharges, can impair cardiac repolarization causing
transient QTc prolongation [100]. Potential mechanisms of periictal QTc prolongation include
cerebral dysregulation, ictal hypoxemia and hypercapnia, cardiorespiratory interactions,
sympathetic stimulation, release of stress hormones and cardiac dysfunction [96, 101].
Generalized tonic-clonic seizures are a risk factor for sudden cardiac death, and cause QTc
shortening due probably to seizure-related release of catecholamines, hyperkalemia, and
acidosis [96]. The increased QT dispersion is explained by autonomic dysfunction with
increased sympathetic tone, and subtle perivascular and interstitial fibrosis, which have been
described in epilepsy [102, 103].
In order to reduce the risk of, or prevent, sudden cardiac death, 12-lead ECG should be
performed in every patient with epilepsy, in order to identify those at high risk, and, therapy
may include antiarrhythmic medication and implantation of cardiac combined pacemaker–
defibrillator devices [96]. Cardiogenic syncope is often a difficult differential diagnosis for
seizures, and long QT with recurrent syncope has been mistaken for epilepsy, and, epileptic
seizures, probably due to cerebral hypoperfusion, have been described in patients with
congenital long QT [96, 104]. Mutations of ionic channels could affect both heart and brain
function, thereby leading to a susceptibility to epilepsy and cardiac arrhythmias [96].
8. Hematologic diseases and ventricular arrhythmia risk
Anemia and red blood cells transfusions have been associated with arrhythmias. Several
electrocardiographic changes were previously mentioned in patients with anemia, including
prolonged QT intervals, ST segment depression, inverted T waves, increased R amplitude after
stress test [105]. Anemia was associated with prolonged QT intervals in hypertensive [106] and
end stage renal disease patients [107], as well. Associations between the QT interval and serum
ferritin level [108] and anisocytosis [106], respectively, were mentioned. Scheller et al. [109]
reported a gradual prolongation of the QT and QTc interval in normovolemic anemia. Anemia
may increase cardiac output and heart rate, may lead to eccentric left ventricular hypertrophy,
activation of the sympathetic nervous system, stimulation of the renin angiotensin aldosterone
system, and is closely associated with chronic inflammation and increased oxidative stress
[106, 110]. Tissue hypoxia and changes in blood flow patterns due to low hemoglobin may
play an atherogenic role [110]. The pathophysiological link between anemia and prolonged
QT intervals and ventricular arrhythmia risk is, probably, hypoxia and decreased myocardial
oxygen supply [106].
Jaja et al [111] reported a blunted autonomic cardiovascular response to changes in posture in
patients with sickle cell anemia. Left ventricular systolic and diastolic dysfunction, increased
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QTc intervals and QT dispersions and late ventricular potentials were found in patients with
beta-thalassemia, a genetic cause of anemia, due to reduced synthesis of beta-globin chains [112,
113]. Several mechanisms explain increased sudden cardiac death in patients with thalassemia,
including iron overload thalassemic cardiomyopathy, with patchy cardiac iron depostition
(due to intensive blood transfusions), changes in calcium homeostasis, elevated prostaglandin
E2 to prostacyclin ratio, increased interleukin 1 level and lipid peroxidation [106, 113, 114].
Athar et al. reported that packed red blood cells (PRBC) transfusions were independently
associated with an increased risk of new onset cardiac arrhythmias and conduction abnor‐
malities in patients with acute myocardial infarction [64]. Multiple factors contributed to the
development of atrial fibrillation in the setting of acute myocardial infarction, including
pericarditis, atrial ischemia, infarction, changes in autonomic tone, metabolic abnormalities,
increased atrial pressures and inflammation [64]. The inflammatory process, exacerbated by
PRBC transfusion, tissue hypoxia, exacerbations of cardiac ischemia and reinfarctions result‐
ing from deficiencies in the ability of stored packed red blood cells to deliver oxygen to tissue,
may explain the appearance of ventricular arrhythmias [64].
A significant correlation was found between QT dispersion and platelet count in healthy
centenarians, hypothesizing that a reduced number of platelets and the maintenance of normal
QT dispersion may contribute to the extreme longevity and protects centenarians from
cardiovascular events [115].
Anthracyclines, used in therapy of patients with hematological malignancies, may have cardio‐
toxic effects, and the typical cardiac manifestations include cardiomyopathy, QT prolongation,
ventricular ectopy and torsade de pointes [35, 116]. High intermittent doses and excessive
cumulative doses increase the risk of cardiomyopathy and fatal arrhythmias, risk factors
including age, female gender, hypertension, preexisting cardiac diseases, electrolyte imbalan‐
ces, associated therapy with other QT prolonging drugs [35, 117]. Long term cardiac monitor‐
ing of patients is needed, in order to prevent sudden cardiac death and cardiac
decompensation.
9. Conclusions
Sudden cardiac death, due to fatal ventricular arrhythmias, continues to be an important public
health problem in developed countries. A high ventricular arrhythmia risk has been reported
in several noncardiac diseases, including metabolic, liver, blood, neurological and psychiatric
disorders. The most common mechanisms were: autonomic and electrolyte imbalances, ion
channel remodeling, cardiomyopathies, increased oxidative stress and QT prolonging drugs.
Most of the mentioned studies used standard 12-lead ECG and surrogate markers of ventric‐
ular arrhythmia risk (QT interval duration, QT dispersion and signal averaged ECG), but
several papers reported ventricular arrhythmias, as well.
Considering that there are no guidelines for the prevention and therapy of arrhythmias
appearing in most of extracardiac disorders, the present review highlighted important
epidemiological and pathophysiological issues related to this topic.
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Selected patients could benefit from electrocardiographic monitoring, specific therapy and
avoidance of QT prolonging drugs, decreasing the burden of sudden cardiac death. Large
follow up studies are needed, controlling for previous QT interval durations, arrhythmias,
coronary heart disease and cardiovascular risk factors, in order to assess the prevalence of
ventricular arrhythmias in noncardiac diseases, to identify further mechanisms and risk factors
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